Post hoc analysis of the phase 3 ATTRIBUTE-CM trial (632 patients with ATTR-CM): higher NT-proBNP and lower serum TTR were each independently associated with death or CV hospitalisation, and acoramidis reduced risk regardless of baseline levels.
Secondary analysisn = 632
Ilonze et al. Natriuretic Peptide and Transthyretin and Their Relationship With Clinical Outcomes: Results From ATTRIBUTE-CM, a Randomized Controlled Trial